Slide 1: Strong order intake and increased sales contributed to sharp improvement in margins
Strong order intake and increased sales contributed to sharp improvement in margins Getinge Q4 2024 Mattias Perjos, CEO Agneta Palmér, CFO
Slide 2: Key takeaways
Key takeaways Q4 2024 • Order intake grew by 11.0% whereof 7.4% organically and net sales increased by 11.8% whereof 9.2% organically • Margins positively impacted by price, leverage from volume, product mix and productivity • The financial position remains solid • Proposed dividend: 4.60 SEK/Share
Slide 3: Key activities and events
Key activities and events Q4 2024 Sustainability and Quality Offering and customers • In November, FDA published a letter to • Paragonix Technologies received FDA 510(k) clearance for Health Care Providers on its website, the innovative KidneyVault, designed to protect donor repeating the informatio
Slide 4: Intention is to phase out the Surgical Perfusion portfolio during 2025
Intention is to phase out the Surgical Perfusion portfolio during 2025 Steadily declining ...and margins Exit the Surgical Perfusion ..for more profitable growth market share*... category.. in ECLS and Transplant Care 15% 15% 10% HL40 HCU40 9% 7% 7% 2018 2019 2020 2021 2022 2023 Surgical Perfusion d
Slide 5: Strong top-line performance in the quarter
Strong top-line performance in the quarter Order Intake and Net Sales Bridge Q4 2023 – Q4 2024 Order Intake Net Sales Organic Organic change +11.9% -0.3% +4.3% +7.4% change +11.7% +12.9% +4.8% +9.2% +11.0% +11.8% 181 205 736 6 171 792 9,273 11,071 8,351 SEK M SEK M 9,903 Q4 2023 Acute Care Life Scie
Slide 6: Margins positively impacted by growth
Margins positively impacted by growth Adjusted Gross Profit and EBITA Bridge Q4 2023 – Q4 2024 Adjusted Gross Profit Adjusted EBITA Adj GM,% Margin development Q4 2024 58.3 41.3 43.5 50.6 +3.8 pp Adj GP (Q4 2023) (56.5) (30.2) (39.6) (46.4) +0.7 pp Adj OPEX +0.2 pp D&A +1.4 pp FX +21.9% 218 240 550
Slide 7: Strong performance shining through in free cash flow and leverage
Strong performance shining through in free cash flow and leverage Capital efficiency and financial position Strong Free Cash Flow … and leverage is still below 2.5x 2.0 1.5 1.6 1.4 1.4 1.7 2.0 1.0 0.9 1.5 1.6 (1.2x excl. 0.4 0.3 pension liabilities) Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q4 2023 Q1
Slide 8: Some selected key activities during an eventful 2024
Some selected key activities during an eventful 2024 February May June September Launch of Servo TwinView FDA letter on ECLS/IABP Launch of Poladus 150 Acquisition of Paragonix March May September December Getinge celebrates 120 years Capital Market Update HLS/PLS CE reinstatement Record sales Full
Slide 9: Let's delve a bit into Paragonix Technologies…
Let’s delve a bit into Paragonix Technologies… February May June September Launch of Servo TwinView FDA letter on ECLS/IABP Launch of Poladus 150 Acquisition of Paragonix March May September December Getinge celebrates 120 years Capital Market Update HLS/PLS CE reinstatement Record sales Full year 2
Slide 10: Paragonix is the clear market leader within transplant care
Paragonix is the clear market leader within transplant care Ambition is to support more than 10 000 transplant patients in 2025 2024 2025 Deploy excellent clinical data readouts Maintain Clinical Leadership with robust for both LUNG- and BAROguard 4 year survival data Lung Heart Cases Cases +65 % Ex
Slide 11: Some reflection and follow-up on the FDA letter in May...
Some reflection and follow-up on the FDA letter in May... February May June September Launch of Servo TwinView FDA letter on ECLS/IABP Launch of Poladus 150 Acquisition of Paragonix March May September December Getinge celebrates 120 years Capital Market Update HLS/PLS CE reinstatement Record sales
Slide 12: "What has been the impact on sales?"
Categories concerned by the FDA letter in May was about 7% of total sales IABP and ECLS in US* 7% Getinge total net sales “What has been the impact on sales?” R12 May 2024 93% Rest of business * Hardware and consumables, excluding service Getinge │ Presentation │ Q4 Report 2024 January 28, 2024
Slide 13: Since May, share of sales have remained on a similar level
Since May, share of sales have remained on a similar level IABP and ECLS in US* IABP and ECLS in US* 7% 7% May 2024 Getinge total FDA Getinge total net sales net sales R12 May 2024 R12 Dec 2024 93% 93% Rest of business Rest of business * Hardware and consumables, excluding service Getinge │ Presenta
Slide 14: We track well according to plan towards our financial target in 2028
We track well according to plan towards our financial target in 2028 What we shared in Capital Market Update in May 2024… …and how we are progressing towards normalization Getinge’s structurally motivated EBITA margin 2024-2028 Quality management According to plan Mix management Better than plan Adj
Slide 15: Net sales for 2025 expected to increase by 2-5% organically
Outlook 2025 Net sales for 2025 expected to increase by 2-5% organically Getinge │ Presentation │ Q4 Report 2024 January 28, 2024
Slide 16: Summary
Summary Getinge │ Presentation │ Q4 Report 2024 January 28, 2024
Slide 17: Key takeaways
Key takeaways Summary Q4 and Full year 2024 • Consistently strong performance on both topline and margins in Q4 • Record net sales for full year 2024 • Strengthened Free Cash Flow and solid financial position • Outlook for 2025: organic net sales growth of 2-5% Getinge │ Presentation │ Q4 Report 202
Slide 18: Q&A
Q&A Getinge │ Presentation │ Q4 Report 2024 January 28, 2024
Slide 19: Thank you
Thank you Getinge │ Presentation │ Q4 Report 2024 January 28, 2024
Slide 20: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 21: Getinge – Passion for Life
“= Se A GETINGE PASSION FOR LIFE